Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(27 sites)

United States

The University of California, San Francisco, San Francisco, California

Bascom Palmer Eye Institute/University of Miami, Miami, Florida

Emory University, Atlanta, Georgia

Massachusetts Eye and Ear, Boston, Massachusetts

University of Michigan- Kellogg Eye Center, Ann Arbor, Michigan

Duke Eye Center, Durham, North Carolina

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon

University of Pennsylvania, Scheie Eye Institute, Philadelphia, Pennsylvania

Retina Foundation of the Southwest, Dallas, Texas

Baylor College of Medicine, Houston, Texas

University of Wisconsin- Madison, Madison, Wisconsin

Belgium

Ghent University Hospital, Ghent

Brazil

Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP), São Paulo

Canada

Hospital for Sick Children, Toronto, Ontario

McGill University Health Centre for Innovative Medicine, Montreal, Quebec

Denmark

Rigshospitalet and University of Copenhagen, Glostrup Municipality

France

Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique, Montpellier

Centre de maladies rares CHNO des Quinze Vingt, Paris

Germany

Universitätsklinikum Tübingen, Tübingen

Italy

ASST Santi Paolo e Carlo Hospital, University of Milan, Milan

AOU Università degli Studi della Campania Luigi Vanvitelli, Naples

Netherlands

Amsterdam University Medical Center - Locatie AMC, Amsterdam

Radboud Universitair Medisch Centrum, Nijmegen

Het Oogziekenhuis Rotterdam, Rotterdam

United Kingdom

Oxford Eye Hospital, Headington, Oxford

University of Edinburgh / NHS Lothian, Edinburgh

Moorfields Eye Hosptial, London